Jounce Therapeutics to Announce Second Quarter 2020 Financial Results and Host Conference Call on Friday, August 7, 2020
July 31 2020 - 8:00AM
Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company
focused on the discovery and development of novel cancer
immunotherapies and predictive biomarkers, today announced that it
will report second quarter 2020 financial results and provide a
corporate update before market open on Friday, August 7, 2020.
Jounce Therapeutics’ management team will host a live conference
call and webcast at 8:00 a.m. ET.
Conference Call and WebcastTo access the
conference call, please dial (866) 916-3380 (domestic) or (210)
874-7772 (international) and refer to conference ID 3898328. The
live webcast can be accessed under “Events & Presentations” in
the Investors and Media section of the company’s website at
www.jouncetx.com. The webcast will be archived and made available
for replay on the company’s website approximately two hours after
the call and will be available for 30 days thereafter.
About Jounce TherapeuticsJounce Therapeutics,
Inc. is a clinical-stage immunotherapy company dedicated to
transforming the treatment of cancer by developing therapies that
enable the immune system to attack tumors and provide long-lasting
benefits to patients through a biomarker-driven approach. Jounce
currently has four development-stage programs, two of which are
clinical-stage: vopratelimab, a monoclonal antibody that binds to
and activates ICOS, and JTX-4014, a PD-1 inhibitor intended for
combination use with Jounce’s broader pipeline. Vopratelimab is
currently being assessed in a Phase 2 clinical trial, EMERGE, and
Jounce plans to initiate an additional Phase 2 biomarker trial
using TISvopra for patient selection, SELECT, to assess
vopratelimab in combination with JTX-4014. Jounce’s IND-enabling
preclinical programs include JTX-8064, a LILRB2 receptor
antagonist, and JTX-1811, a monoclonal antibody designed to
selectively deplete T regulatory cells in the tumor
microenvironment. For more information, please visit
www.jouncetx.com.
Investor Contact:Komal JoshiJounce
Therapeutics, Inc.(857) 320-2523kjoshi@jouncetx.com
Jounce Therapeutics (NASDAQ:JNCE)
Historical Stock Chart
From Mar 2024 to Apr 2024
Jounce Therapeutics (NASDAQ:JNCE)
Historical Stock Chart
From Apr 2023 to Apr 2024